Tower Research Capital LLC (Trc) Esperion Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.29 Billion
- Q1 2025
A detailed history of Tower Research Capital LLC (Trc) transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 4,207 shares of ESPR stock, worth $7,530. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,207
Previous 6,708
37.28%
Holding current value
$7,530
Previous $14,000
57.14%
% of portfolio
0.0%
Previous 0.0%
Shares
29 transactions
Others Institutions Holding ESPR
# of Institutions
195Shares Held
121MCall Options Held
171KPut Options Held
679K-
Black Rock Inc. New York, NY14MShares$25 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$21 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT10.9MShares$19.6 Million0.09% of portfolio
-
Two Seas Capital LP Rye, NY9.95MShares$17.8 Million0.18% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.69MShares$17.4 Million0.32% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $119M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...